Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deflazacort. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deflazacort SCHEMBL24497637 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL4019 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL2598076 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL22502722 | 0.99 | NR3C1 (0.98) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL4259541 | 0.98 | NR3C1 (0.95) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL17941674 | 0.97 | NR3C1 (0.94) | NR3C1PGRHIF1ANR1I2CNR1 | |
| SCHEMBL13653579 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL887173 | 0.92 | NR3C1 (0.84) | NR3C1PGRHIF1ANR1I2LMNA | |
| 21-Desacetyldeflazacort SCHEMBL30754690 | 0.90 | NR3C1 (0.81) | NR3C1PGRHIF1ANR1I2CNR1 | |
| SCHEMBL13653592 | 0.89 | NR3C1 (0.80) | NR3C1PGRHIF1ANR1I2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15755 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108610-A1 | Drug-Resistant Immune Cells and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2026-04-23 | — | — | US | claimed |
| US-20260108602-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | OSASUNA THERAPEUTICS SA (CH) | 2026-04-23 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-3858340-B1 | DIETHYL-[6-(4-HYDROXYCARBAMOYL-PHENYL-CARBAMOYLOXY-METHYL)-NAPHTHALEN-2-YL-METHYL]-AMMONIUM CHLORIDE IN COMBINATION WITH AT LEAST ONE GLUCOCORTICOID CORTICOSTEROID FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY | ITALFARMACO SPA (IT) | 2026-04-08 | — | — | EP | claimed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | claimed |
| WO-1998015568-A2 | NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | NICOX S.A. (FR) | 1998-04-16 | — | — | WO | claimed |
| WO-1997041144-A1 | NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS | G.D. SEARLE & CO. (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1997021722-A1 | PREPARATION OF (11β,16β)-21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-5'H-PREGNA-1,4-DIENO[17,16-D]OXAZOLE-3,20-DIONE | GRUPPO LEPETIT S.P.A. (IT) | 1997-06-19 | — | — | WO | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |